Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine

Yoshiro Saikawa, Tetsuro Kubota, Tsong Hong Kuo, Toshiharu Furukawa, Hirokazu Tanino, Masahiko Watanabe, Kyuya Ishibiki, Masaki Kitajima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

An attempt was made to evaluate the enhancement of the antitumor activity of cisplatin (DDP) by buthionine sulfoximine (BSO) in vitro and in vivo. In the in vitro study, pre-treatment with BSO (5, 10 and 25 mM) increased the antitumor activity of DDP against the gastric cancer cell lines MKN-28 and MKN-45, whereas BSO alone exhibited only slight antitumor activity (inhibition rate, 20-30%). In the in vivo study, the antitumor effects of DDP against human gastric cancer xenografts St-15 and SC-1-NU in BALB c nu nu mice were enhanced pretreatment with BSO, which was administered intraperitoneally at a dose of 500 mg/kg according to a schedule of qd × 3. BSO alone showed no antitumor effects against these tumors in nude mice. The side effects (assessed in terms of death rate and body weight loss) associated with the maximum tolerated dose of DDP (9 mg/kg) were not increased by BSO pretreatment. As BSO increased the antitumor activity of DDP without a corresponding increment of its toxicity, BSO appears to be a promising agent for further study.

Original languageEnglish
Pages (from-to)787-793
Number of pages7
JournalJapanese Journal of Cancer Research
Volume84
Issue number7
Publication statusPublished - 1993 Jul

Fingerprint

Buthionine Sulfoximine
Cisplatin
Stomach Neoplasms
Maximum Tolerated Dose
In Vitro Techniques
Heterografts
Nude Mice
Weight Loss
Appointments and Schedules
Body Weight
Cell Line
Mortality

Keywords

  • Buthionine sulfoximine
  • Cisplatin
  • Human gastric cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. / Saikawa, Yoshiro; Kubota, Tetsuro; Kuo, Tsong Hong; Furukawa, Toshiharu; Tanino, Hirokazu; Watanabe, Masahiko; Ishibiki, Kyuya; Kitajima, Masaki.

In: Japanese Journal of Cancer Research, Vol. 84, No. 7, 07.1993, p. 787-793.

Research output: Contribution to journalArticle

Saikawa, Y, Kubota, T, Kuo, TH, Furukawa, T, Tanino, H, Watanabe, M, Ishibiki, K & Kitajima, M 1993, 'Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine', Japanese Journal of Cancer Research, vol. 84, no. 7, pp. 787-793.
Saikawa, Yoshiro ; Kubota, Tetsuro ; Kuo, Tsong Hong ; Furukawa, Toshiharu ; Tanino, Hirokazu ; Watanabe, Masahiko ; Ishibiki, Kyuya ; Kitajima, Masaki. / Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. In: Japanese Journal of Cancer Research. 1993 ; Vol. 84, No. 7. pp. 787-793.
@article{acfc84feeb734897a4ba76075471b5e3,
title = "Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine",
abstract = "An attempt was made to evaluate the enhancement of the antitumor activity of cisplatin (DDP) by buthionine sulfoximine (BSO) in vitro and in vivo. In the in vitro study, pre-treatment with BSO (5, 10 and 25 mM) increased the antitumor activity of DDP against the gastric cancer cell lines MKN-28 and MKN-45, whereas BSO alone exhibited only slight antitumor activity (inhibition rate, 20-30{\%}). In the in vivo study, the antitumor effects of DDP against human gastric cancer xenografts St-15 and SC-1-NU in BALB c nu nu mice were enhanced pretreatment with BSO, which was administered intraperitoneally at a dose of 500 mg/kg according to a schedule of qd × 3. BSO alone showed no antitumor effects against these tumors in nude mice. The side effects (assessed in terms of death rate and body weight loss) associated with the maximum tolerated dose of DDP (9 mg/kg) were not increased by BSO pretreatment. As BSO increased the antitumor activity of DDP without a corresponding increment of its toxicity, BSO appears to be a promising agent for further study.",
keywords = "Buthionine sulfoximine, Cisplatin, Human gastric cancer",
author = "Yoshiro Saikawa and Tetsuro Kubota and Kuo, {Tsong Hong} and Toshiharu Furukawa and Hirokazu Tanino and Masahiko Watanabe and Kyuya Ishibiki and Masaki Kitajima",
year = "1993",
month = "7",
language = "English",
volume = "84",
pages = "787--793",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine

AU - Saikawa, Yoshiro

AU - Kubota, Tetsuro

AU - Kuo, Tsong Hong

AU - Furukawa, Toshiharu

AU - Tanino, Hirokazu

AU - Watanabe, Masahiko

AU - Ishibiki, Kyuya

AU - Kitajima, Masaki

PY - 1993/7

Y1 - 1993/7

N2 - An attempt was made to evaluate the enhancement of the antitumor activity of cisplatin (DDP) by buthionine sulfoximine (BSO) in vitro and in vivo. In the in vitro study, pre-treatment with BSO (5, 10 and 25 mM) increased the antitumor activity of DDP against the gastric cancer cell lines MKN-28 and MKN-45, whereas BSO alone exhibited only slight antitumor activity (inhibition rate, 20-30%). In the in vivo study, the antitumor effects of DDP against human gastric cancer xenografts St-15 and SC-1-NU in BALB c nu nu mice were enhanced pretreatment with BSO, which was administered intraperitoneally at a dose of 500 mg/kg according to a schedule of qd × 3. BSO alone showed no antitumor effects against these tumors in nude mice. The side effects (assessed in terms of death rate and body weight loss) associated with the maximum tolerated dose of DDP (9 mg/kg) were not increased by BSO pretreatment. As BSO increased the antitumor activity of DDP without a corresponding increment of its toxicity, BSO appears to be a promising agent for further study.

AB - An attempt was made to evaluate the enhancement of the antitumor activity of cisplatin (DDP) by buthionine sulfoximine (BSO) in vitro and in vivo. In the in vitro study, pre-treatment with BSO (5, 10 and 25 mM) increased the antitumor activity of DDP against the gastric cancer cell lines MKN-28 and MKN-45, whereas BSO alone exhibited only slight antitumor activity (inhibition rate, 20-30%). In the in vivo study, the antitumor effects of DDP against human gastric cancer xenografts St-15 and SC-1-NU in BALB c nu nu mice were enhanced pretreatment with BSO, which was administered intraperitoneally at a dose of 500 mg/kg according to a schedule of qd × 3. BSO alone showed no antitumor effects against these tumors in nude mice. The side effects (assessed in terms of death rate and body weight loss) associated with the maximum tolerated dose of DDP (9 mg/kg) were not increased by BSO pretreatment. As BSO increased the antitumor activity of DDP without a corresponding increment of its toxicity, BSO appears to be a promising agent for further study.

KW - Buthionine sulfoximine

KW - Cisplatin

KW - Human gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=0027202178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027202178&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 787

EP - 793

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -